Skip to content
Search

Latest Stories

Coughs can spread Covid-19 beyond two metres: Cambridge study

A new study has shown that Covid-19 can spread between unmasked people at a distance of more than two metres even outdoors.

A team of engineers from the University of Cambridge used computer modelling to quantify how droplets spread when people cough.


They found that the two-metre rule was arbitrary and that social distancing alone was not enough to stop the spread of the virus.

The team also found that individual coughs vary widely, and that the ‘safe’ distance could have been set at anywhere between one to three or more metres.

The results, published in the journal Physics of Fluids, suggest that social distancing is not an effective mitigation measure on its own, and underline the importance of vaccination, ventilation and masks.

Despite the focus on hand-washing and surface cleaning in the early days of the pandemic, it’s been clear for nearly two years that Covid-19 spreads through airborne transmission.

Infected people can spread the virus through coughing, speaking or even breathing, when they expel larger droplets that eventually settle or smaller aerosols that may float in the air.

“I remember hearing lots about how Covid-19 was spreading via door handles in early 2020, and I thought to myself if that were the case, then the virus must leave an infected person and land on the surface or disperse in the air through fluid mechanical processes,” said professor Epaminondas Mastorakos from Cambridge’s Department of Engineering, who led the research.

“We’re all desperate to see the back of this pandemic, but we strongly recommend that people keep wearing masks in indoor spaces such as offices, classrooms and shops... There’s no good reason to expose yourself to this risk as long as the virus is with us.”

Dr Shrey Trivedi, the paper’s first author, said that there was a lot of variation between coughs.

“One part of the way that this disease spreads is virology: how much virus you have in your body, how many viral particles you expel when you speak or cough,” he said.

The researchers found that there isn’t a sharp cut-off once the droplets spread beyond two metres. When a person coughs and isn’t wearing a mask, most of the larger droplets will fall on nearby surfaces.

However, smaller droplets, suspended in the air, can quickly and easily spread well beyond two metres. How far and how quickly these aerosols spread will depend on the quality of ventilation in the room.

In addition to the variables surrounding mask-wearing and ventilation, there is also a high degree of variability in individual coughs.

“Each time we cough, we may emit a different amount of liquid, so if a person is infected with Covid-19, they could be emitting lots of virus particles or very few, and because of the turbulence they spread differently for every cough,” said Trivedi.

“Even if I expel the same number of droplets every time I cough, because the flow is turbulent, there are fluctuations,” said Mastorakos. “If I’m coughing, fluctuations in velocity, temperature and humidity mean that the amount someone gets at the two-metre mark can be very different each time.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less